# OnCo record surufatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/surufatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "surufatinib" ;
  schema:name "Surufatinib"@en ;
  schema:alternateName "sulfatinib"@en, "Sulanda"@en ;
  schema:description "Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours."@en ;
  schema:url <https://onco.cc/drugs/surufatinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=surufatinib> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor" ;
  onco:approval "CN 2020: Advanced non-pancreatic neuroendocrine tumours; pancreatic neuroendocrine tumours from 2021" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/csf1r/> ;
  onco:companies <https://onco.cc/companies/hutchmed/> .